Álvarez-FernándezM., Sanz-FloresM., Sanz-CastilloB, et al.Therapeutic relevance of the PP2A-B55 inhibitory kinase MASTL/Greatwall in breast cancer. Cell Death Differ, 25(5):828-840 (2018).
4.
ChenC.-C., LiB., MillmanS. E., et al.Vitamin B6 addiction in acute myeloid leukemia. Cancer Cell, 37(1):71–84 (2020)
5.
ZhangZ., ZhouC., LiX., et al.Loss of CHD1 promotes heterogeneous mechanisms of resistance to AR-targeted therapy via chromatin dysregulation. Cancer Cell, 37(4):584–598 (2020).
6.
BaslanT., MorrisJ. P.IV, ZhaoZ., et al.Ordered and deterministic cancer genome evolution after p53 loss. Nature, 608(7924):795–802 (2022)
7.
Alonso-CurbeloD., HoY.-J., BurdziakC., et al.A gene-environment induced epigenetic program initiates tumorigenesis. Nature, 590(7847):642–648 (2021)
8.
XueY., MartelottoL., BaslanT., et al.An approach to suppress the evolution of resistance in BRAFV600E-mutant cancer. Nature Medicine, 23(8):929–937 (2017).
9.
PrasannaP. G., CitrinD. E., HildesheimJ., et al.Therapy-induced senescence: Opportunities to improve anticancer therapy. JNCI, 113(10):1285–1298 (2021).
10.
ChenH.-A., HoY.-J., MezzadraR., et al.Senescence rewires microenvironment sensing to facilitate anti-tumor immunity. Cancer Discovery, 13(2):432–453 (2023).
11.
RuscettiM., MorrisJ. P.IV, MezzadraR., et al.Senescence-induced vascular remodeling creates therapeutic vulnerabilities in pancreas cancer. Cell, 181:424–441 (2020).
12.
PaffenholzS. V., SalvagnoC., HoY.-J., et al.Senescence induction dictates response to chemo- and immunotherapy in preclinical models of ovarian cancer. PNAS, 119(5):e2117754119 (2022).
